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Microarray technology is a powerful tool
allowing simultaneous investigation of
gene expression changes of thousands of
genes in response to various stimuli. Large-
scale and even whole transcriptome analyses
have successfully been applied in various
fields including variation in budding yeast
(Brem et al. 2002), development of
Drosophila melanogaster (Arbeitman et al.
2002), variation in primates (Enard et al.
2002), and human cancer (Ramaswamy
et al. 2003). Class identiﬁcation and predic-
tion of defined end points using gene
expression arrays have shown promising
results in oncology (Alizadeh et al. 2001;
Ramaswamy et al. 2001; Van de Vijver
et al. 2002).
The application of gene expression
analysis in toxicology has led to the emer-
gence of the discipline of toxicogenomics.
We anticipate that toxicogenomics will
greatly improve the sensitivity, accuracy,
and speed of toxicologic investigations.
Toxicogenomics assumes that toxicity is
accompanied by changes in gene expression
that are either causally linked or represent a
response to toxicity. Indeed, researchers
have been able to link toxicity with expres-
sion changes of single genes or whole
groups of genes (Hamadeh et al. 2002c;
Ruepp et al. 2002; Suter et al. 2003).
A transcriptome-wide overview of
altered expression patterns can assist the
mechanistic understanding of underlying
changes induced by chemicals (Hamadeh
et al. 2002b). This requires a comprehen-
sive knowledge of the biological system
under investigation, and only known genes
are considered for analysis. This functional
approach is also promising for the genera-
tion and testing of toxicity hypotheses
(Donald et al. 2002; Zhang et al. 2002) or
the identification of perturbed pathways
(Wang et al. 1999; Zimmermann et al.
2003). Furthermore, identiﬁcation of toxic
mechanisms is valuable for risk assessment
because it allows extrapolation of the hazard
in humans.
Predictive toxicology is based on the
hypothesis that similar treatments leading
to the same end point will share comparable
changes in gene expression. Several investi-
gators have used gene expression profiling
for the classiﬁcation of toxicants in rodents
(Bulera et al. 2001; Hamadeh et al. 2002a;
Thomas et al. 2001; Waring et al. 2001b).
These studies varied in design and number
of compounds investigated, but all indi-
cated the potential of toxicogenomics in
predictive risk assessment.
A major challenge in predicting toxico-
logic end points based on transcriptional
data lies in discriminating changes due to
interanimal variation or experimental back-
ground noise from treatment-related
changes. Compounds may directly affect
expression of certain well-characterized,
compound-specific genes. These com-
pound-specific genes are not suited for
discrimination between different classes of
compounds. Drugs, in contrast to other
toxic substances, have pharmacologic as
well as toxicologic effects that might affect
gene expression. These two effects can, but
need not, be related. Despite these con-
founding factors, gene expression analysis
after treatment with various compounds
that result in the same toxicologic end
point should enable identification of a
toxic ﬁngerprint.
Various methods are used to analyze
large-scale gene expression data. Unsuper-
vised methods widely reported in the litera-
ture include agglomerative clustering
(Eisen et al. 1998), divisive clustering
(Alon et al. 1999), K-means clustering
(Everitt 1974), self-organizing maps
(Kohonen 1995), and principal component
analysis (Joliffe 1986). Support vector
machines (SVMs), on the other hand,
belong to the class of supervised learning
algorithms. Originally introduced by
Vapnik and co-workers (Boser et al. 1992;
Vapnik 1998), they perform well in differ-
ent areas of biological analysis (Schölkopf
and Smola 2002). Given a set of training
examples, SVMs are able to recognize
informative patterns in input data and
make generalizations on previously unseen
samples. Like other supervised methods,
SVMs require prior knowledge of the clas-
sification problem, which has to be pro-
vided in the form of labeled training data.
Used in a growing number of applications,
SVMs are particularly well suited for the
analysis of microarray expression data
because of their ability to handle situations
where the number of features (genes) is
very large compared with the number of
training patterns (microarray replicates).
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Male rats were treated with various model compounds or the appropriate vehicle controls. Most
substances were either well-known hepatotoxicants or showed hepatotoxicity during preclinical
testing. The aim of the present study was to determine if biological samples from rats treated with
various compounds can be classiﬁed based on gene expression proﬁles. In addition to gene expres-
sion analysis using microarrays, a complete serum chemistry profile and liver and kidney
histopathology were performed. We analyzed hepatic gene expression proﬁles using a supervised
learning method (support vector machines; SVMs) to generate classiﬁcation rules and combined
this with recursive feature elimination to improve classiﬁcation performance and to identify a com-
pact subset of probe sets with potential use as biomarkers. Two different SVM algorithms were
tested, and the models obtained were validated with a compound-based external cross-validation
approach. Our predictive models were able to discriminate between hepatotoxic and nonhepato-
toxic compounds. Furthermore, they predicted the correct class of hepatotoxicant in most cases.
We provide an example showing that a predictive model built on transcript proﬁles from one rat
strain can successfully classify proﬁles from another rat strain. In addition, we demonstrate that the
predictive models identify nonresponders and are able to discriminate between gene changes
related to pharmacology and toxicity. This work conﬁrms the hypothesis that compound classiﬁca-
tion based on gene expression data is feasible. Key words: liver, microarray, predictive toxicology,
rat, support vector machines, toxicogenomics. Environ Health Perspect 112:1236–1248 (2004).
doi:10.1289/txg.7036 available via http://dx.doi.org/ [Online 1 July 2004]Several studies have shown that SVMs
typically tend to outperform other classiﬁ-
cation techniques in this area (Brown et al.
2000; Furey et al. 2000; Yeang et al. 2001).
In addition, the method proved effective in
discovering informative features such as
genes that are especially relevant for the
classification and therefore might be criti-
cally important for the biological processes
under investigation. A signiﬁcant reduction
of the gene number used for classiﬁcation is
also crucial if reliable classifiers are to be
obtained from microarray data. A proposed
method to discriminate the most relevant
gene changes from background biological
and experimental variation is gene shaving
(Hastie et al. 2000). However, we chose
another method, recursive feature elimina-
tion (RFE) (Guyon et al. 2002), to create
sets of informative genes.
The liver is a primary site for drug
metabolism and is frequently involved in
adverse drug reactions. Thus, hepatotoxic
compounds were chosen for our toxico-
genomic studies. In this study 28 hepato-
toxic compounds and 3 nonhepatotoxic
compounds were investigated. Time-
matched controls dosed with the corre-
sponding vehicles were used to allow
discrimination between temporal and com-
pound-induced changes. This is essential
for large-scale transcriptome analysis, as
extensive circadian gene expression patterns
have recently been reported in the liver and
heart of the mouse (Kita et al. 2002; Panda
et al. 2002; Storch et al. 2002).
Depending on the substance and cate-
gory of toxicity, different time points were
chosen for classiﬁcation, as manifestation of
toxicity was observed earlier for certain com-
pounds than for others. Clinical chemistry,
hematology, and histopathology were used
to assess toxicity of each individual animal.
Models for discrimination of toxic and
nontoxic substances as well as models spec-
ifying the category of toxicity were built
using data from a variety of toxicity studies.
The hypothesis that unknown blinded
compounds could accurately be classified
based solely on gene expression proﬁles was
subsequently tested. In the majority of
cases, SVMs were able to predict toxicity as
well as the mode of toxicity. The potential
for obtaining the same level of predictivity
with only a small number of carefully
selected genes was investigated. This subset
of genes includes potential biomarkers for
hepatotoxicity.
Materials and Methods
Animal Treatment
Permission for animal studies was obtained
from the local regulatory agencies, and all
study protocols were in compliance
with animal welfare guidelines. Male
HanBrl:Wistar rats approximately 12 weeks
of age (300 g ± 20%) were obtained from
BRL (Füllinsdorf, Switzerland). The animals
were housed individually in Macrolone
(Tecniplast GmbH, Hohenpeissenberg,
Germany) cages with wood shavings as bed-
ding at 20°C and 50% relative humidity
in a 12-hr light/dark rhythm with free
access to water and Kliba 3433 rodent pel-
lets (Provimi Kliba AG, Kaiseraugst,
Switzerland). For the WY14643 study, male
Sprague-Dawley Crl:CD(SD)IGS.BR
rats approximately 6 weeks of age
(200 g ± 20%) were obtained from Charles
River Ltd. (Margate, U.K.)
Animals were dosed with test com-
pounds or the corresponding vehicles orally
or by ip, iv, or sc injections and sacrificed
at specified times by CO2 inhalation
(Table 1). Immediately preceding sacriﬁce,
terminal blood samples for clinical chem-
istry investigations were collected from the
retroorbital sinus. Liver samples from the
left medial lobe were removed immediately
and placed into RNALater (Ambion,
Austin, TX, USA) for RNA extraction and
gene expression analysis (Table 1). The
exposure period for each compound was
based on reports in the literature and
results from pilot studies using histopathol-
ogy and clinical chemistry anchoring to
assess toxicity. Thus, for unknown com-
pounds best results are expected if several
time points (e.g., 6 hr, 1 day, and 1 week)
are tested. 
Clinical Chemistry
The following determinations were made
from the serum: blood urea nitrogen
(BUN), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), γ-gluta-
myltransferase (GGT), lactate dehydroge-
nase (LDH), sorbitol dehydrogenase
(SDH), alkaline phosphatase (ALP),
5´-nucleotidase (5´-NT), glutamate dehy-
drogenase (GLD), urea, glucose, creati-
nine, bilirubin, total protein, albumin,
globulins, total cholesterol, triglycerides,
phospholipids, fatty acids, bile acids,
sodium, potassium, chloride, calcium, and
phosphorus.
Histology
Representative liver samples were fixed in
10% neutral-buffered formalin. One addi-
tional liver sample from the cranial half of
the left lateral lobe was placed in Carnoy
fixative for glycogen staining. All samples
were processed using routine procedures
and embedded in Paraplast (Sherwood
Medical Ltd., Tullamore, Ireland). Tissue
sections approximately 2–3 µ were cut and
stained with hematoxylin and eosin or
periodic acid-Schiff for glycogen. Fat Red
7B stain (Fluka, Buchs, Switzerland) was
performed on frozen formalin-fixed
sections to visualize lipid deposits.
Sample Preparation and
Hybridization
RNA isolation, processing, and hybridiza-
tion were essentially carried out as recom-
mended by Affymetrix (Affymetrix, Santa
Clara, CA, USA) with minor modifica-
tions [Supplemental data (http://ehp.
niehs.nih.gov/txg/members/2004/7036/
7036supplement.pdf)]. 
Data Acquisition and Preprocessing
Primary data were obtained by laser
scanning (Hewlett Packard, Palo Alto, CA,
USA) and collated using the Affymetrix
Microarray Suite Version 5.0 software
(Affymetrix). Before performing any
downstream analysis, data were pre-
processed in a standardized way. First, the
gene expression values of every single
microarray experiment were rescaled to a
mean value of zero and a standard devia-
tion of 1 to establish comparability across
all samples. Because single outlying expres-
sion values occur rather frequently and are
likely to affect any analysis method, a
modified version of the Nalimov outlier
test (Kaiser and Gottschalk 1972) was
applied to identify these potential artifacts.
Expression values reported as outliers were
replaced by the respective mean values.
The test was performed separately for each
classification group (i.e., class of toxicity).
In contrast to the published method, our
modified version does only one round of
outlier removal rather than multiple itera-
tions. A normal distribution model is cal-
culated for the expression levels to be
tested, and outliers are removed at a
99% confidence level. As a final prepro-
cessing step, the expression values were
rescaled so that the expression of each sin-
gle gene across multiple arrays has a mean
value of zero and a standard deviation of 1.
This transformation increases the numeri-
cal stability of the SVM algorithm and
facilitates the assessment of the relative
importance (weight) of single genes within
a reduced feature set. Again, this was per-
formed separately for each classification
group.
Support Vector Machines
A detailed introduction into theory and
application of SVMs is beyond of the scope
of this article. We refer the interested reader
to the available literature (Cristianini
and Shawe-Taylor 2000; Schölkopf and
Smola 2002) and the Supplemental Data
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Table 1. Histopathology and clinical chemistry results of rats used included in the SVM training set.
Substance/dose/ Vehicle/route Expected binary class/
CAS no./supplier of administration 4-MOT class Liver histopathology Serum clinical chemistry
Aﬂatoxin B1 Saline + 0.5%  Toxic/direct Hepatocellular hypertrophy, apoptosis, Increased bile acids, bilirubin,
4 mg/kg, 24 hr  DMSO/ip inﬂammation, glycogen depletion, AST, ALT, LDH, ALP, 5´-NT
1162-65-8 bile duct proliferation
Sigma
Bromobenzene  Corn oil/ip Toxic/direct Centrilobular to midzonal hepatocellular Increased bilirubin, 5´-NT, albumin;
3 mmol/kg, 24 hr hydropic swelling, necrosis with decreased triglycerides
108-86-1 mixed inﬂammation
Aldrich
Carbon tetrachloride (CCl4) Corn oil/po Toxic/direct Hepatocellular degeneration, single-cell Increased GGT, liver triglycerides;
2 mg/kg, 24 hr necrosis, inﬂammation, microvesicular steatosis decreased glucose, albumin
56-23-5
Fluka
Hydrazine Saline/ip Toxic/direct Hepatocellular necrosis with inﬂammation, Increased 5´-NT
60 mg/kg, 24 hr mild microvesicular steatosis
302-01-2 
Sigma
Thioacetamide Saline/ip Toxic/direct Hepatocellular vacuolation and necrosis Increased GGT, AST, ALT, ALP,5´-NT;
50 mg/kg, 24 hr decreased glucose, triglycerides, 
62-55-5 cholesterol, protein
Sigma-Aldrich
1,2-Dichlorobenzene Corn oil/ip Toxic/direct Centrilobular to midzonal hepatocellular Increased ALP, albumin; decreased 
4,500 mmol/kg, 24 hr hydropic swelling, necrosis with mixed triglycerides
95-50-1 inﬂammation
Fluka
Coumarin  Corn oil/po Toxic/direct Hepatocellular hypertrophy, single-cell Increased total protein, GLD
200 mg/kg, 24 hr necrosis, lymphocytic inﬁltration
91-64-5,
Sigma 
Acetaminophen  Saline + 0.5%  Toxic/direct Centrilobular hepatocellular vacuolation, Increased albumin; decreased 
2 g/kg, 24 hr DMSO/po single-cell necrosis, inﬂammation triglycerides
103-90-2
Fluka
Amineptine Saline/ip Toxic/steatosis Hepatocellular microvesicular steatosis, Increased GGT, ALP, cholesterol;
0.5 mmol/kg/day, 2 days glycogen depletion decreased triglycerides
57574-09-1
Servier Laboratories
Amiodarone 7.5% gelatine/ip Toxic/steatosis Hepatocellular microvesicular steatosis, Increased GGT, 5´-NT; decreased
100 mg/kg/day, 4 days glycogen depletion serum and increased liver 
1951-25-3 triglycerides
Sigma
Rx74 (Antidiabetic) Klucel/po Toxic/steatosis NDa NDa
250 mg/kg/day, 5 days
Not available 
Roche
Rx75 (Antidiabetic) Klucel/po Toxic/steatosis NDa NDa
100 mg/kg/day, 5 days
Not available
Roche
Rx10 (Antidiabetic) Klucel/po Toxic/steatosis NDb NDb
500 mg/kg/day, 5 days
Not available 
Roche
Rx99 (5-HT6 antagonist) H2O/po Toxic/steatosis Hepatocellular microvesicular steatosis Increased ALT, GGT; increased liver
400 mg/kg/day, 14 days lipids and phospholipids
Not available 
Roche
Chlorpromazine 1  Saline/iv Toxic/cholestasis ND Increased bilirubin, glucose;
15 mg/kg, 6 hr decreased triglycerides
69-09-0
Sigma
Chlorpromazine 2  Saline/iv Toxic/cholestasis Hepatocellular microvesicular steatosis, Increased glucose; decreased
15 mg/kg, 6 hr glycogen depletion triglycerides, protein
69-09-0
Sigma
Cyclosporin A  10% intralipid/iv Toxic/cholestasis NSF Increased bile acids, bilirubin, GGT
30 mg/kg, 6 hr
59865-13-3
Alexis
Continued, next page(http://ehp.niehs.nih.gov/txg/members/
2004/7036/7036supplement.pdf)]. 
All SVM classifications were based on
the free available software package LIBSVM,
2.36, which was downloaded from the
World Wide Web (Chang and Lin 2001).
The source code was modiﬁed according to
our needs and compiled to run on the oper-
ating system IRIX, version 6.5, (Silicon
Graphics, Inc., Mountain View, CA, USA).
Extensions such as parameter optimization,
feature selection, enhanced cross-validation
(CV) options, the one-versus-all training
scheme, and report generation were imple-
mented in a C library on top of LIBSVM.
Choice of Parameters
A linear kernel k(xi,xj) = 〈xi,xj〉 was chosen
for the SVM, as higher order correlation
functions could easily lead to overinterpre-
tation of the data, given the unfavorable
ratio of features and replicates. LIBSVM
offers two different SVM formulations for
classification: C-SVM and υ-SVM. These
formulations use different parameters for
adjusting the accuracy versus margin
tradeoff but should produce comparable
solutions. We tried both formulations and
tuned their respective parameters for
optimal CV performance.
To handle the multiple class situation,
we applied the one-versus-all training para-
digm. Using this approach, a set of binary
SVMs is created, each of which separates
the samples of one class (positive examples)
from all remaining training data (negative
examples). Because the number of negative
examples usually outweighs the number of
positive examples in this scheme, there is
always a risk of losing sensitivity for the
smaller class. However, practice showed
that no additional class bias had to be
introduced after appropriate values for the
C or υ parameter had been determined for
each single SVM. Optimization of these
crucial parameters was done in an iterative
manner. We typically started with either a
C value set to 1.0 or a υ value of 0.5 and
performed a complete gene selection run.
Optimization of SVMs using different fea-
ture numbers suggested improvements in
the initial settings as well as a sensible range
for the parameters. Feature selection was
then repeated with the new settings, and
individual SVMs were again tuned to
determine good parameters for different
gene numbers. This process led to a notice-
ably improved classiﬁcation performance.
Classiﬁer Validation
The predictive power of individual SVMs
was primarily rated by their CV perfor-
mance. However, as our main interest was
to estimate the generalization properties of
classiﬁers with respect to new compounds,
we did not select the frequently applied
leave-one-out or randomization-based
schemes. Instead, all microarrays that
resulted from the treatment with a certain
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Table 1. Continued
Substance/dose/ Vehicle/route Expected binary class/
CAS no./supplier of administration 4MOT class Liver histopathology Serum clinical chemistry
Glibenclamide  7.5% gelatine/iv Toxic/cholestasis Hepatocellular hypertrophy Increased ALT; decreased glucose
25 mg/kg, 6 hr
10238-21-8
Roche
Phalloidin  Saline/iv Toxic/cholestasis Hepatocellular necrosis, hemorrhage, Increased bilirubin, bile acids,
0.8 mg/kg, 6 hr glycogen depletion 5´-NT, ALP, AST, ALT, LDH, SDH;
17466-45-4 decreased cholesterol, phospholipids
Sigma
Methylene dianiline Corn oil/po Toxic/cholestasis Single-cell necrosis of bile duct
100 mg/kg, 6 hr epithelium, inﬂammation Increased bilirubin, bile acids, GGT,
101-77-9 5´-NT, glucose, phospholipids
Fluka
WY14643  Corn oil/po Toxic/PP Increased hepatocellular mitoses, Increased ALP, glucose, SDH
250 mg/kg, 14 days slight glycogen depletion, increased liver
50892-23-4 weight (7 days)
Sigma-Aldrich
Rx90 (PPAR-δ agonist) PBS/po Toxic/PP Liver enlargement, diffuse hepatocellular Increased AST, ALT
180 mg/kg/day, 14 days hypertrophy
Not available
Roche
Rx53 (PPAR-α,γ co-agonist) PBS/po Toxic/PP Increased liver weight, hepatocellular Decreased cholesterol, protein
0.9 mg/kg/day, 14 days hypertrophy and cytoplasmic granulation
Not available
Roche
Rx60 (PPAR-α,γ co-agonist) PBS/po Toxic/PP Increased liver weight, hepatocellular  Increased serum ALP; decreased
1.5 mg/kg/day, 14 days hypertrophy and cytoplasmic granulation,  protein, bilirubin
Not available increased mitoses, single-cell necrosis with 
Roche mixed inﬂammation
Rx51 (PPAR-α,γ co-agonist)  PBS/po Toxic/PP Increased liver weight, hepatocellular Increased ALP; decreased
0.5 mg/kg/day, 14 days hypertrophy and cytoplasmic granulation cholesterol, bilirubin, protein
Not available
Roche
Rx50 (PPAR-α,γ co-agonist)  PBS/po Toxic/PP Increased liver weight, hepatocellular Increased ALP, glucose; decreased
4 mg/kg/day, 14 days hypertrophy and cytoplasmic granulation protein, bilirubin, cholesterol
Not available
Roche
Abbreviations: DMSO, dimethylsulfoxide; ND, not done; NSF, no signiﬁcant ﬁndings; PBS, phosphate-buffered saline; PP, peroxisome proliferator. 
aNo clinical chemistry or histopathology data were available from animals used for gene proﬁling, but repeated dosing with this compound in animals used for other measurements
resulted in microvesicular steatosis. bNo clinical chemistry or histopathology data were available from animals used for gene proﬁling. Microvesicular steatosis was not detected in rats
with this treatment schedule. However, in vitro treatment of primary rat hepatocytes inhibited β-oxidation and resulted in fat accumulation.compound (regardless of dose and time
point) were left out as a whole group in
one CV cycle. Whenever CV is combined
with feature selection, special care must be
taken to avoid any bias leading to over-
optimistic performance estimates. There-
fore, we applied external CV exclusively
where feature selection was done separately
for each group of left-out examples,
thereby avoiding the use of information
from the excluded examples in the feature
selection process. Although the ﬁnal classi-
fier is built on all available training exam-
ples, the described method was used to
determine the optimal number of genes as
well as the parameter settings. As a conse-
quence, we expect that the resulting classi-
fiers are less influenced by the given
selection of compounds and that CV pro-
vides a more realistic estimate for the gen-
eralization on new compounds.
Quantitative measures for training and
CV performance were sensitivity and speci-
ﬁcity values as well as the Matthews corre-
lation coefﬁcient (MCC),
where TP = number of true positives,
TN = number of true negatives, FP = num-
ber of false positives, and FN = percentage
of false negatives. The MCC is commonly
used as a measure of the predictive power
of a system that gives categoric variables as
output (Matthews 1975). It was our main
performance indicator.
When several SVMs showed exactly the
same CV result, performance on the train-
ing set was also taken into account. If this
still yielded equal results, we ﬁnally selected
the simplest model (i.e., smallest number
of support vectors and smallest number of
features).
Gene Selection
Although SVMs can easily tolerate the
high-dimensional gene space typical of
microarray studies, most of the features are
usually irrelevant for the classification task
and only introduce noise. To obtain a
meaningful decision function that general-
izes well, the number of variables must be
reduced as much as possible.
Various methods exist for selecting
discriminating features for classification
purposes; most deal with variables
individually. RFE overcomes some
deficiencies of this univariate approach
(Guyon et al. 2002). Basically, RFE is a
greedy backward elimination method.
Starting with all features (except for
Affymetrix control genes), a ranking is pro-
duced based on the relative importance of a
particular feature in the SVM decision
function. A certain fraction of the least
important variables is then removed, and
the process is repeated iteratively until the
feature list is empty. The precise order of
features might change from iteration to
iteration. Because of the multivariate prop-
erties of the SVM algorithm, each feature
ranking takes into account (at least to some
extent) correlations between single vari-
ables. Evaluating the classification perfor-
mance at each step makes it possible not
only to identify a suitable subset of descrip-
tors but also to determine how many of
them are actually needed for a reliable clas-
sification. Redundant features also tend to
be eliminated during RFE, typically result-
ing in very compact feature sets (Guyon
et al. 2002).
We implemented RFE on top of the
libsvm software. In the beginning, a user-
definable fraction of the least important
genes is removed in each iteration. After
reaching a certain threshold number, only
one more gene is eliminated in each step.
We experimented with several values for
the fraction and lower threshold values to
further improve the classification perfor-
mance of our classiﬁers.
Presentation of Support Vector
Machine Results
A binary SVM discriminating between two
classes is trained by presenting the training
samples of one class (A) as positive exam-
ples while samples belonging to the other
class (B) act as negative examples. An SVM
prediction (i.e., the value of the decision
function when a new data example is
tested) is simply a real number called the
discriminant. If the discriminant is posi-
tive, the example is considered belonging
to class A. Similarly, a negative number
would indicate membership in class B. The
absolute value of the discriminant can be
regarded as a measure of conﬁdence for the
classiﬁcation.
If there are more than two distinct
classes, several binary classifiers must be
combined to obtain a prediction for a new
sample. When applying the one-versus-all
scheme (see above), n classiﬁers have to be
created for n classes. A new data example is
then tested with all these SVMs and there-
fore the result consists of n real values from
which the most probable class assignment
must be inferred. Classiﬁcation results can
be presented as plots of discriminant values
that were obtained from a set of SVMs
(Figure 1). A unique assignment is possible
if only one SVM produces a positive
output for a certain sample. If a treatment
group is not classiﬁed uniformly, we assign
the corresponding compound to a category
by majority vote, with 60% as the cutoff.
Sometimes two- or three-dimensional
scatter plots were produced for visualizing
the class separation of one model
(Figure 2). These diagrams map all training
and test examples into one coordinate sys-
tem and often reveal some (expected or
unexpected) internal structure of the data
such as subclusters or single outliers. The
dimensionality reduction is achieved
by plotting linear combinations of
features against each other. Coefficients
are obtained from the SVM decision func-
tion [Supplemental data (http://ehp.
niehs.nih.gov/txg/members/2004/7036/
7036supplement.pdf)].
Results 
Histopathology and Clinical
Chemistry—Proﬁles Used for
Training Support Vector Machine
Models
We used SVMs as a supervised learning
method to generate classification rules. It
was of crucial importance to provide train-
ing labels on the basis of solid evidence.
Therefore, a complete serum chemistry
profile and liver histopathology were per-
formed on virtually all rats treated with
various model compounds or the appropri-
ate vehicle controls. This information in
conjunction with published data provided
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Figure 1. Classification of five vehicle control or
five WY14643-treated rats. Gene expression pro-
files of Sprague-Dawley rat livers treated either
with vehicle or WY14643 were assessed with a
model built exclusively on data from Wistar rats.
Results of the SVM for peroxisomal proliferation
are shown. All profiles from treated rats yield
clearly positive discriminants, indicating that the
transcriptional changes identify the substance to
cause peroxisomal proliferation. Controls have
clearly negative values, indicating no match with
the fingerprint of the peroxisomal proliferation
class.the basis to allocate gene expression proﬁles
to a speciﬁc training class (Table 1).
Gene Expression Analysis
Gene expression profiles from individual
rat livers treated with vehicle or test com-
pounds were analyzed using the Affymetrix
U34A GeneChip. All microarrays included
in the analysis fulfilled our established
quality parameters [Supplemental data
(http://ehp.niehs.nih.gov/txg/members/
2004/7036/7036supplement.pdf)]. All
treatments caused transcriptional changes
with respect to their corresponding
time-matched controls. In all studies,
> 150 genes were expressed above back-
ground and showed at least a 2-fold modu-
lation with a p-value < 0.05 (two-tailed,
unpaired t test). 
Assessment of Time Effects in
Vehicle Control–Treated Rat Livers
(Early versus Late)
Supervised analysis of gene expression data
suffers if parameters other than the investi-
gated effects correlate with the classes
for which one tries to identify typical
ﬁnger-prints. The studies evaluated in this
article differed in vehicle, application route,
and time point (Table 1). We assumed that
time-dependent effects could be the
confounding factor with the most notice-
able impact on the results. Thus, we ana-
lyzed gene expression patterns from
vehicle-treated animals (i.e., controls) at
various time points. A classification
attempt was made using the same time
points used for the toxicity classiﬁcations in
this article (early class is 6 hr, late class is
24 hr up to several days). We obtained a
prediction accuracy of 70% and an MCC
of 0.41, whereas random shuffling of the
analyzed microarrays gave MCC values
close to zero, indicating that the observed
variations can be attributed to time effects.
Using this approach, 14 genes were
selected as the best set of discriminative
features. These results conﬁrmed that there
are indeed some observable time-related
effects [Supplemental data, Table 1
(http://ehp.niehs.nih.gov/txg/members/
2004/7036/7036supplement.pdf)].
However, because time points of the con-
trol microarrays typically vary within one
class of toxicity, we expected the SVM to
identify the time-dependent genes as not
relevant for the toxicity predictions.
Actually, only one gene of this subset
appeared in one toxicity classifier
(rc_AA799616_at) but with a low weight.
Effect of the Rat Strain
Because different rat strains are widely
used in toxicology, we investigated the
effect of strain differences of Wistar and
Sprague-Dawley rats for classification
based on transcript profiles. Our database
consisting of Wistar rat data was used to
generate an SVM. Subsequently, gene
expression profiles from vehicle control
and WY14643-treated Sprague-Dawley
livers were used to assess whether the
model would correctly classify individual
animals from another rat strain. All five
controls were clearly identified as controls
(Figure 1). Their transcript proﬁles yielded
negative discriminants for all SVMs except
the control SVM, where positive values
marked those profiles as controls. Animals
treated with 250 mg/kg WY14643 were
unanimously assigned to the peroxisomal
proliferator class. Here, discriminant val-
ues were positive only for the peroxisomal
SVM and negative for all other categories.
As those results indicated that gene expres-
sion profiles from Sprague-Dawley and
Wistar rats are comparable, transcript pro-
files from WY14643 were included in
further models.
Generation of Toxic/Nontoxic and
Multitoxicity Models
We generated a binary classifier for the
discrimination of vehicle controls and ani-
mals treated with a toxic compound. In
addition, to predict the mode of action,
multitoxicity models were also created. For
both the binary and the multiclass case, we
used the same data set for training the
SVMs, applying either the C-formulation
or the υ-formulation of the algorithm. To
extract smaller sets of truly discriminative
genes, we integrated RFE in the process of
model building. This enabled us to study
performance parameters such as sensitivity
and speciﬁcity under CV in relation to the
number of genes used.
All the models were evaluated with an
external CV scheme that omits a whole
treatment group (typically five animals)
per cycle. Therefore, a complete RFE run
had to be carried out for each of the
60 groups (see “Materials and Methods”).
Furthermore, all SVMs were validated
with an independent test set that con-
tained different doses and time points of
the same substances used for training as
well as some new compounds. 
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Figure 2. Identification of nonresponding animal. Gene expression profiles from galactosamine-treated
rats and vehicle controls were tested using the 4MOT model. Results from the direct-acting SVM (based
on 104 genes) are projected onto a three-dimensional coordinate system for better visualization
[Supplemental data (http://ehp.niehs.nih.gov/txg/members/2004/7036/7036supplement.pdf)]. Top left: gene
expression profiles from direct-acting compounds. Bottom right: profiles from the remaining categories
cluster together. Classification results are in line with histopathology and clinical chemistry data. The
shift of the nonresponding animal toward the direct-acting group is a hint that gene expression proﬁling
could be more sensitive than classical end points used in this study.The results obtained were similar for
C-SVMs and υ-SVMs, although the num-
ber of used genes at the point of optimal
performance seemed to be smaller for the
υ-SVM. However, C-SVM most often
outperformed  υ-SVM in terms of
classiﬁcation accuracy. Of all 26 toxic sub-
stances, C-SVM could not detect 4,
whereas υ-SVM missed 6 compounds. A
clear majority of the control groups were
correctly classified under CV. In this
respect there was no pronounced difference
between the two formulations.
Toxic/Nontoxic Model
Results for the binary toxic/nontoxic
classification are summarized in Table 2.
The test set of 63 vehicle-control groups
demonstrates how well those models
generalize on previously unseen data
[details in Supplemental data (http://ehp.
niehs.nih.gov/txg/members/2004/7036/
7036supplement.pdf)]. Not every single
microarray, but all groups were correctly
identified as controls using the described
voting procedure. Almost 90% of the toxic
test groups were correctly classiﬁed as toxic
using C-SVM. The model did not produce
any false-positive predictions. However,
there were some false-negatives, as not all
toxic treatments could be recognized as
toxic. 
Multiclass Model
As the next step we aimed at predicting the
mode of toxicity. For this purpose, a
control class and three categories of toxicity
were initially deﬁned: cholestasis, steatosis,
and direct acting. Subsequently, we added
peroxisome proliferator-activated receptor α
(PPAR-α) agonists as a separate class with-
out any loss in prediction accuracy
(Table 3). We refer to this as the 4-modes-
of-toxicity (4MOT) model. This is an
imperfect simplification of the classifica-
tion task, as some of the compounds show
more than one form of hepatotoxicity,
depending on dose and time. Therefore,
time points at which a specific toxicity
was most apparent were selected for the
analysis.
We generated five different SVMs
following the one-versus-all approach, that
is, each of the models was trained to dis-
criminate between a certain class of toxicity
and the set union of all other expression
proﬁles. In a ﬁrst step, the individual classi-
fiers were built and optimized separately
using the same CV procedure described
before. Subsequently, a class assignment for
each single microarray in the training or
test set was done by combining the output
of the five models (Tables 4 and 5). In
most cases the prediction was unanimous,
that is, just one SVM delivered a positive
discriminant and the others returned
negative values (e.g., Figure 3A–C). In
cases where a profile obtained more than
one positive discriminant value or only
negative numbers, the biggest value deter-
mined the classification (e.g., Figure 4).
The optimal gene number for classiﬁcation
depends on the category of toxicity. For
example, peroxisomal proliferation/PPAR
agonists could be recognized with one sin-
gle marker gene. Nevertheless, the final
classifier used four features because of our
strategy of simplifying the model by also
minimizing the number of support vectors
(see “Materials and Methods”). The four
top probe sets represent only two distinct
genes, acetyl-Coenzyme A acyltransferase 1
(peroxisomal 3-oxoacyl-Coenzyme A thio-
lase) and cytochrome P450 4A1. Both
genes are well-known PPAR-α–responsive
genes, and the corresponding upregulation
has been described extensively in the litera-
ture (Hansmannel et al. 2003; Lee et al.
2003).
The model for the control group
required the most features (122). Perfor-
mance again was rather similar for υ-SVM
and C-SVM. In the case of υ-SVM,
274 distinct features were used altogether
for discriminating among the ﬁve classes of
toxicity. However, a reduction to 86 fea-
tures did not lead to a significant loss in
predictivity, indicating that this set could
be used for an assay in a 96-well format
(data not shown).
Categories of toxicity differ not only in
optimal feature number but also in predic-
tion accuracy. Under CV as well as in the
test set, all toxicant categories are recog-
nized with a very high specificity, whereas
the controls are identified with a high
Toxicogenomics | Steiner et al.
1242 VOLUME 112 | NUMBER 12 | August 2004 • Environmental Health Perspectives
Table 2. Performance of the toxic/nontoxic models and summarized results of the binary (toxic/nontoxic)
classiﬁcation.a
Arrays/groups for classiﬁcation ν-SVM C-SVM
Classiﬁcation under external CV
26 treatment groups 20 of 26 treatments correct 22 of 26 treatments correct
116 arrays 89 of 116 arrays correct 90 of 116 arrays correct
34 control groups 32 of 34 groups correct 32 of 34 groups correct 
163 arrays 154 of 163 arrays correct 154 of 163 arrays correct
Classiﬁcation of test set
19 treatment groups 16 of 19 treatments correct 17 of 19 treatments correct
91 arrays 74 of 91 arrays correct 74 of 91 arrays correct
63 control groups 63 of 63 (all groups correct) 63 of 63 (all groups correct)
332 arrays 322 of 332 arrays correct 327 of 332 arrays correct
aDuring RFE, the least informative 5% of genes were removed in each iteration starting with all features (genes) down to
64 genes. After that, only a single gene was removed in one step. The number of features ﬁnally selected was 63 for the
ν-SVM and 228 for the C-SVM. In the case of ν-SVM, RFE was carried out with ν = 0.1. The optimized ν of the selected
(using 63 genes) is 0.203. For C-SVM we set C to 0.008 during RFE and ended up with C = 0.00429 for the selected iteration.
Both SVMs were equally successful in classifying vehicle controls, but the C-SVM was slightly better in identifying toxic
treatments.
Table 3. Performance assessment of the ﬁve SVMs that form the 4MOT model.a
Class Features CV speciﬁcity CV sensitivity CV MCC Optimized Test speciﬁcity Test sensitivity Test MCC
Classiﬁcation with υ-SVM
Direct 101 1 0.86 0.92 0.0377 1 0.75 0.83
PP 4 1 1 1 0.01 1 1 1
Cholestasis 19 0.99 0.6 0.71 0.0193 0.99 0.83 0.82
Steatosis 28 1 0.54 0.72 0.0744 1 0.91 0.95
Control 122 0.78 0.94 0.75 0.111 0.84 0.98 0.86
Classiﬁcation with C-SVM
Direct 38 1 0.84 0.9 0.0176 1 0.75 0.83
PP 16 1 1 1 0.0222 1 1 1
Cholestasis 32 0.98 0.57 0.61 0.1 0.98 0.83 0.81
Steatosis 50 0.99 0.67 0.75 0.00869 1 0.91 0.95
Control 228 0.78 0.94 0.74 0.00429 0.8 0.98 0.83
aResults are shown for υ-SVM and C-SVM. The RFE procedure was identical to that described in Table 2. The number of features selected was typically smaller for υ-SVM than for
C-SVM. Both types of SVM were comparably successful in classiﬁcation.sensitivity. This means that our model
produces virtually no false-positive out-
comes but at the cost of some false-negative
results. All treatment groups within the
direct-acting category are either correctly
classiﬁed or, in the case of aﬂatoxin, at least
recognized as treated with a toxic substance
(Table 4). Phalloidin is another example
that was identified as toxic, but profiles
were classified into two toxicity cate-
gories—cholestatic and direct acting.
Amiodarone, glibenclamide, and chlorpro-
mazine 1 were not recognized as toxic.
Classification of our test set again con-
ﬁrmed the good performance of the model.
The classification of 332 test control
microarrays with an error rate of 0.6% is
remarkable. Using the criteria described
above, the success rate in classifying the
corresponding 63 control groups is 100%
(as seen before in the binary classiﬁcation).
Identiﬁcation of Nonresponding
Animals
Galactosamine treatment of rats usually
leads to hepatitis associated with necrosis
and inflammation. Animals were treated
once with 400 mg/kg galactosamine or
vehicle only and sacrificed after 24 hr. In
four of five galactosamine-treated animals,
there was clear evidence of toxicity assessed
by hematology, clinical chemistry, and
histopathology; one animal was a nonre-
sponder. Gene expression profiles of indi-
vidual animals were tested using the 4MOT
model described previously. Classification
results are in perfect agreement with the
assessment using conventional end points.
However, gene expression profiling seems
to be more sensitive than clinical chemistry
and histopathology, as the data point corre-
sponding to the nonresponding rat is clearly
shifted toward the direct-acting group
(Figure 2). 
Pharmacologic Effects Are
Differentiated from Toxicologic
Effects
Pharmacologically active substances can alter
gene expression, but a predictive model for
hepatotoxicity should not confuse a sub-
stance with a desired pharmacologic effect
with an unwanted toxic outcome. Three
nonhepatotoxic but pharmacoactive sub-
stances were tested with the SVM models.
Although 100 mg/kg gentamicin (sc) led to
nephrotoxicity at 24 hr, no hepatotoxicity
was associated with it, nor was hepatotoxic-
ity detected with deprenyl or lazabemide. All
three nonhepatotoxic substances were cor-
rectly classiﬁed as nontoxic using both, the
toxic/nontoxic as well as the 4MOT model
(Figure 3). These results show that our toxi-
city classiﬁers can distinguish well between
pharmacologic effects without toxicity and
toxicologically relevant transcriptional
changes.
Classiﬁcation of Hepatotoxic
Compounds with Mechanisms of
Toxicity not Represented in Our
Database—Lipopolysaccharide,
Phenobarbital, and Indomethacin
Compounds with mechanisms of toxicity
(MOTs) not represented in our training set
were used to investigate how they would be
classiﬁed by our models. The toxic/nontoxic
model had the easier task, as dissimilarity
with control proﬁles would already indicate
some toxicity-related abnormality in gene
expression. The 4MOT model had to clas-
sify an unrepresented profile to one of the
ﬁve available classes.
Lipopolysaccharide (LPS) (4 mg/kg iv)
was investigated 6 and 24 hr after dosing
and identiﬁed as toxic by the toxic/nontoxic
model. The 4MOT model classified four
animals as steatotic and one as cholestatic
after 6 hr (Figure 4A). After 24 hr four ani-
mals were also classiﬁed as steatotic and one
as direct acting. No sample was misclassi-
ﬁed as a control. Phenobarbital (80 mg/kg
ip) was also investigated at 6 and 24 hr. At
24 hr all animals ﬁt into the steatotic cate-
gory (Figure 4B). At 6 hr, four proﬁles were
most similar to the steatotic group and one
to the cholestatic group. In this case most
discriminant values were very low, indicat-
ing differences with respect to the existing
classes. Another interesting example was
indomethacin, which was administered
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Table 4. Classiﬁcation of individual microarrays and treatment groups in training set and overview of CV
and test results for a υ-SVM–based model discriminating between different MOTs.a
Expected toxicity  CV accuracy  CV accuracy  Misclassiﬁcation
Treatment category (binary) (4MOT) in 4MOT
Chlorpromazine 1 Cholestatic 1/5b 1/5b 4 controlsb
Chlorpromazine 2  Cholestatic 4/5 4/5 1 control
Cyclosporin A Cholestatic 4/5 4/5 1 control
Glibenclamide Cholestatic 0/5b 0/5b 5 controlsb
Methylene dianiline Cholestatic 5/5 5/5 –
Phalloidin Cholestatic 3/5 2/5 1 direct acting, 2 controls
Aﬂatoxin B1 Direct acting 2/3 1/3 1 cholestatic, 1 control
1,2-Dichlorobenzene Direct acting 5/5 5/5 –
APAP Direct acting 3/5 3/5 2 controls
Bromobenzene Direct acting 5/5 5/5 –
CCl4 Direct acting 5/5 5/5 –
Coumarin Direct acting 5/5 5/5 –
Hydrazine Direct acting 5/5 5/5 –
Thioacetamide 1 Direct acting 3/5 3/5 2 controls
Rx50 (PPAR-α, γ)P P 5/5 5/5 –
Rx53 (PPAR-α, γ)P P 2/4b 2/4b 2 controlsb
Rx51 (PPAR-α, γ)P P 5/5 5/5 –
Rx60 (PPAR-α, γ)P P 5/5 5/5 –
WY14643 PP 5/5 5/5 –
Rx90 (PPAR-δ)P P 5/5 5/5 –
Rx99 (5HT6) Steatotic 3/5 3/5 2 controls
Amineptine Steatotic 4/5 4/5 1  control
Amiodarone Steatotic 0/5b 0/5b 5 controlsb
Rx74 (anitdiabetic) Steatotic 3/3 3/3 –
Rx75 (anitdiabetic) Steatotic 2/3 2/3 1 control
Rx10 (anitdiabetic) Steatotic 3/3 3/3 –
aPredictions for individual microarrays and treatment groups as a whole were obtained using different voting schemes
described in the text. A compound-based external CV method was used for the assessment of model quality. The upper
part of the table reports the number of microarrays correctly classiﬁed under CV conditions, either with correct mecha-
nism of action predicted (column 4) or with at least a toxic effect recognized (column 3). bMisclassiﬁcations.
Table 5. Performance summary of the υ-SVM–based model discriminating between different MOTs.
Arrays/groups for classiﬁcation Summary
26 treatment groups 20 of 26 treatment groups correct MOT identiﬁed
22 of 26 treatment groups correctly identiﬁed as toxic
116 microarrays 85 of 116 microarrays correctly classiﬁed 
34 control groups 33 of 34 groups correctly identiﬁed as vehicle controls
163 microarrays 160 of 163 microarrays correctly classiﬁed
Classiﬁcation of independent test set
19 treatment groups 15 of 19 treatment groups correct MOT identiﬁed
15 of 19 treatment groups correctly identiﬁed as toxic
91 microarrays 74 of 91 microarrays correctly classiﬁed
63 treatment groups 63 of 63 (all groups correctly identiﬁed)
332 microarrays 330 of 332 microarrays correctly classiﬁedeither as a single high dose (20 mg/kg po;
sample collection at 6 or 24 hr) or as a
repeated low dose (5 mg/kg po; daily dosing
during 1 week). In the liver, minimal to
slight hepatocellular hypertrophy and
decreased glycogen deposition were observed
in animals treated with 20 mg/kg at 24 hr
and in animals treated for 1 week with
5 mg/kg/day. The repeated dosing also
caused tubular dilation in the kidney and
erosive and/or ulcerative inflammations in
the gastrointestinal tract. At 6 hr the sub-
stance was classified as predominately
cholestatic and at 24 hr clearly as steatotic.
After 7 days of dosing, three animals were
classiﬁed as steatotic and two as cholestatic.
These proﬁles had positive discriminants for
three toxicity categories (cholestatic,
steatotic, direct acting). This indicates that
indomethacin is different from our pre-
defined toxicity categories and displays
mixed toxicity (Figure 4C). Most important,
a very clear dissimilarity from the control
group indicated that the indomethacin-
treated animals had been exposed to a toxic
compound, although the mode of toxicity
could not be unequivocally deﬁned.
Discussion 
Gene Expression Proﬁling
The present work aimed to provide
evidence that transcript proﬁles can be used
to distinguish compound-treated rat livers
from controls and to discriminate between
different MOTs. Rats were treated with a
variety of vehicles, and hepatotoxic or non-
hepatotoxic but pharmacologically active
compounds. We focused on hepatotoxicity,
as the liver is a main target for toxic reac-
tions. Various questions were addressed in
the context of predictive toxicity modeling,
including sanimal variability, rat strain dif-
ferences, effect of time, and discrimination
of pharmacologically from toxicologically
induced gene changes. 
Several authors have described the use
of gene expression proﬁling to classify toxi-
cants in rodent liver and thereby demon-
strated the potential of toxicogenomics in
predictive risk assessment (Bulera et al.
2001; Hamadeh et al. 2002a; Thomas et al.
2001; Waring et al. 2001b). We used a
larger number of compounds and selected a
different bioinformatics approach to analyze
the data. New in this study is the modeling
of different categories of toxicity in con-
junction with numeric measures for the
classification confidence. Our results
demonstrate that for different compounds
with similar MOT, the likely toxicologic
end point can be inferred from gene expres-
sion profiles using a database of model
compounds as a training set. Moreover, we
found good correlation of gene expression
changes with histopathologic findings.
These results are consistent with those of a
previously reported study where methapyri-
lene toxicity correlated with the severity of
pathologic changes (Hamadeh et al. 2002c).
Feature Selection
SVMs can handle very high-dimensional
feature spaces, so there is no pressing need
to filter out a small number of genes in a
first step. In contrast to many published
microarray studies, we did not apply strict
cutoffs like 2-fold changes, p-value thresh-
olds, or similar criteria.. These approaches
could easily spoil one of the main advan-
tages of a multivariate classification
method such as SVMs, as prefiltering of
features by common univariate methods
(such as the t test) might remove genes
that do not reach significance when tested
individually but provide useful informa-
tion when taken together with other, cor-
related variables. In contrast, RFE allowed
us to combine feature selection and model
building in a consistent framework, mak-
ing use of the mutual information between
genes (Guyon et al. 2002). We leave it to
the method to eliminate noisy, irrelevant
variables in the process of forming smaller
and smaller subsets of genes with discrimi-
natory power. The approach also helped to
avoid the introduction of a feature selec-
tion bias, which occurs if information
from all experiments is used to reduce the
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Figure 3. Assessment of gentamicin, deprenyl, and lazabemide. Animals
were treated with a high dose of (A) gentamicin (GEN; 100 mg/kg sc,
24 hr), (B) deprenyl (DPR; 20 mg/kg/day, 4 days), or (C) lazabemide (LAZ;
1,000 mg/kg/day, 4 days). No hepatotoxicity was detected with any of
the three treatments. However, nephrotoxicity was evident in GEN-
treated animals. Gene expression signatures in liver tissue were related
to pharmacology without association to hepatotoxicity. Thus, GEN, DPR,
and LAZ were correctly identified as nontoxic. Classification of those
animals with the controls is indicated by the positive discriminant values
for the control SVM. number of genes before any CV is done.
However, it is important to remember that
the gene lists we obtained are in no way a
complete picture of the cellular response
but a redundancy-reduced selection of
markers that together allow a maximum
predictivity.
The relationship between gene number
and classiﬁcation performance was studied
using RFE, and subsequently the optimal
iteration was chosen. Our results indicate
that accurate prediction of toxicity
(including the category of toxicity) can be
achieved using a small set consisting of
a few up to some dozens of features
(Table 3). In the case of the 4MOT
model, the feature number can be reduced
from 274 to 86 without major perfor-
mance impairment. The observation that
more genes do not necessarily translate
into higher predictive accuracy is consis-
tent with previous findings (Ramaswamy
et al. 2003; Thomas et al. 2001), indicat-
ing that it is not necessary to measure the
whole transcriptome or thousands of genes
to predict toxicity. Once initial experi-
ments have led to an optimized set of
relevant informative features, a potentially
faster and cheaper assay could be devel-
oped providing essentially the same classi-
fication performance. Interestingly, using
only the selected features for hierarchical
clustering also resulted in a toxicologically
meaningful result, whereas unsupervised
clustering with all genes often failed at
classifying the animals according to the
criteria of interest (data not shown).
However, it is worth mentioning that
none of the genes in the ﬁnal set is guaran-
teed to act as a good toxicity marker on its
own because we do not rank features
according to their suitability as single
markers (univariate approach) but rather
optimize whole subsets of features (multi-
variate approach). In this setting it is possi-
ble that a gene that does not appear
differentially expressed in two groups can
still contribute useful information by com-
bination with other genes. Therefore, it is
often the signature taken as a whole that
provides the decisive discriminatory
power. Marker gene sets identified with
the described method are especially prone
to show this effect because of the multi-
variate nature of SVMs and the tendency
of the RFE algorithm to eliminate redun-
dant features from the set (Guyon et al.
2002).
As gene expression analysis can also be
applied in vitro (Burczynski et al. 2000;
Waring et al. 2001a), the question arises
whether the list of features obtained could
be used in a cell-based assay. This seems
questionable, as significant differences in
gene expression in vitro compared with
in vivo were reported (Boess et al. 2003).
Therefore, we expect that results concern-
ing discriminative features and their
weights cannot be directly transferred to
in vitro classification systems. In addition,
the evaluation of the compound effects
in vivo is especially important when multi-
ple cell types and possibly multiple organs
are involved in the toxicologic response.
Confounding Effects
A crucial issue when using supervised
classiﬁcation methods is that there must be
solid evidence for the initial assignment of
gene expression profiles to each category.
Therefore, we included only microarrays
from animals where independent evidence
justified allocation to a specific class. In
most cases, histopathologic anchoring was
used, but clinical chemistry and occasion-
ally additional biochemical assays (trigly-
ceride assays, data not shown) were also
considered. Anchoring to conventional end
points was the reason for the heterogeneity
of time points used in the training proce-
dure. This kind of heterogeneity might act
as a confounding factor, introducing
signatures not related to the toxicity classi-
ﬁcation problem itself. Special care must be
taken to ensure that these confounding fac-
tors do not exhibit decisive influence on
the model. The potentially confounding
effect of time was addressed ﬁrst, as several
authors have highlighted extensive circadian
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Figure 4. Classification of lipopolysaccharide, phenobarbital, and
indomethacin. Abbreviations: IND, indomethacin; LPS, lipopolysaccha-
ride; PHB, phenobarbital. (A) Animals were treated with an acute dose of
LPS (4 mg/kg iv) and assessed after 6 hr. Four animals were classiﬁed as
steatotic and one animal as cholestatic (animal 5). (B) Rats were dosed
with PHB (80 mg/kg po) and assessed 24 hr thereafter. All five animals
were considered steatotic. Rats treated with LPS or PHB had very low
positive discriminant values for the toxicity categories, indicating no
good fit with the representative data in the predictive model. However,
the large negative discriminant values of the control SVMs in A, B, and C
clearly indicate that all animals were treated with a toxicant. (C) Animals
were treated with a high dose of IND (5 mg/kg po) and assessed after
1 week. Positive scores were obtained for three different toxic cate-
gories. Obviously, the proﬁles match some characteristics of the ﬁnger-
prints of all three classes at the same time.gene expression changes (Kita et al. 2002;
Panda et al. 2002; Storch et al. 2002). For
this purpose, the same time points (6 hr,
24 hr, and several days) used within our
toxicity models were used to train a two-
class SVM model for classiﬁcation of early
or late time points. A classifier based on
14 genes was obtained, but predictivity was
far from perfect and resulted in a relatively
low MCC of 0.41. (Test MCC values for
the toxicity classifiers were all > 0.80.)
Although these results confirm some time
dependency in our experiments, we have
no reason to assume that this strongly
affects our toxicity models, as we always
combined control profiles from all time
points in the same group for training.
Together with the fact that none of the
genes from the time classiﬁers appeared at a
prominent position (with significant
weight) in the toxicity models, these results
suggest that there is no distinct time bias.
In fact, classification of vehicle controls
from the test set (originating from inde-
pendent studies and including various time
points) was correct in more than 99% of
the cases, which confirms the absence of
time bias for the control component of the
classiﬁer.
Wistar, Sprague-Dawley, and Fischer
rats are all frequently used in risk assess-
ment. There is ample evidence that those
strains vary in their susceptibilities to vari-
ous toxicants or mutagens (Asamoto et al.
1989; Kulkarni et al. 1996). Therefore, we
investigated whether a model built with
Wistar rat expression proﬁles would be pre-
dictive for treatment effects in Sprague-
Dawley rats. PPAR agonists were chosen for
this comparison for pragmatic reasons. At
the time we studied proprietary PPAR
agonists, we were also involved in the
Consortium for Metabonomic Toxicology
(COMET), where liver tissue collection of
WY14643-treated Sprague-Dawley rats
could be included. [COMET has been
formed by Imperial College (London) and
six major pharmaceutical companies. The
objective is to apply metabonomics to the
toxicologic assessment of compounds
(Lindon et al. 2003).] Treated rats as well as
controls fit perfectly into the anticipated
classes. The classification was successful
despite the additional confounding factor
introduced by the fact that the Sprague-
Dawley rats were approximately 6 weeks
younger than the Wistar rats. This
successful class prediction was the rationale
for including those expression profiles in
our predictive models. As the results sug-
gest, the discriminative transcriptional
changes are largely conserved across strains,
although the doses required to produce
comparable toxicity may vary.
Another confounding factor for the
classification task is that pharmaceuticals
not only show a toxic effect on gene regula-
tion but might also influence gene expres-
sion according to their pharmacologic
action. A crucial test for the classiﬁcation of
toxicants based on gene expression proﬁles
is certainly the ability to separate pharmaco-
logic from true toxic effects. Our models
succeeded at classifying three pharmacologi-
cally active, nonhepatotoxic compounds. In
the case of gentamicin, not even the
observed nephrotoxicity led to a false pre-
diction of hepatotoxicity. The classiﬁcation
of these three compounds as nonhepato-
toxic was not due to a general lack of effects
on hepatic gene expression; more than
100 genes were differentially expressed for
these compounds, as assessed by fold
change together with t test (at least 2-fold
change and p-value < 0.05).
Mixed Toxicities
All transcript profiles were assigned to a
specific category, implying that they fit
exactly into one class. However, in reality,
substances often cause mixed toxicities. We
aimed to allocate substances to the best-ﬁt-
ting class, knowing the limitations due to
the potential overlap of effects. Our results
indicate that characteristic gene expression
changes are indeed associated with distinct
classes of toxicants. However, as com-
pounds cannot be put into exclusive bins in
a strict sense, some substances (aflatoxin,
indomethacin, and phalloidin) were pre-
dicted to be associated with multiple toxici-
ties. Aﬂatoxin, for example, needs metabolic
activation to exert its toxic effect. It causes
generation of reactive oxygen species, lipid
peroxidation, glutathione depletion, and
necrosis and therefore has a direct effect on
cells (Liu et al. 1999). On the other hand, it
is a well-known carcinogen (Smela et al.
2001) and is reported to induce both
cholestasis (Unger et al. 1977) and steatosis
(Amaya-Farfan 1999). Based on classical
end points, we decided to allocate aﬂatoxin
to the direct-acting group. The SVM classi-
ﬁcation of gene expression proﬁles, however,
indicated a greater similarity to cholestatic
than to direct-acting compounds. One pos-
sible way to address this problem might be
to generate several one-versus-control cate-
gories and include the aﬂatoxin samples in
both the direct-acting and the cholestatic
classes. Another option would be to exclude
all compounds from training that do not
unambiguously ﬁt into one single category.
Reported effects of indomethacin in rats are
immediately direct, like adenosine triphos-
phate depletion in hepatocytes (Masubuchi
et al. 1998) and a marked decrease in the
hepatic monooxygenase system (Fracasso
et al. 1990). Gene expression proﬁles of rats
dosed with indomethacin were classiﬁed as
cholestatic and steatotic but also matched
the direct-acting group. Clinical chemistry
supported this mixed toxicity prediction to
some extent, as ALP, GGT, AST, and LDH
were increased. Histopathology revealed
hypertrophy and minimal to slight necrosis,
but changes were considered to be adaptive
rather than reflecting an adverse effect. In
patients, however, cases of cholestasis and
steatosis have been reported (Farrel 1994). It
remains to be confirmed whether the
genomics approach is more sensitive than
histopathology in detecting liabilities.
Results classifying galactosamine-treated
rats using the multitoxicity model support
this hypothesis. Galactosamine treatment
leads to hepatitis associated with necrosis
and inflammation, but a high degree of
interanimal variation is well known (Vomel
and Platt 1986). In our study four of five
expression profiles were identified as toxic
while the fifth was classified as control.
This classification as nonresponder was in
agreement with absence of findings using
conventional end points. However, a three-
dimensional plot of the SVM results
revealed a shift of the expression proﬁle of
the nonresponder toward the direct-acting
group (Figure 2 ), suggesting increased
sensitivity of the toxicogenomics approach.
Model Assessment
We used a compound-based external CV
scheme (see “Materials and Methods”) to
obtain more realistic estimates for the classi-
ﬁcation performance and to select a model
from which we can expect a good general-
ization power. It has to be kept in mind
that the compound database is still limited
in size, and we do not know whether our
set of substances is a representative sam-
pling of the complete toxicology space.
Therefore, we cannot completely rule out
some sampling bias, which would render
our performance estimates too optimistic.
Conversely, our CV procedure intrinsically
tends to deliver a rather conservative assess-
ment of the performance, as at least some of
the compounds provide vital information
that is lost as soon as a whole treatment
group is withheld from training. For exam-
ple, glibenclamide (dosed at 25 mg/kg) was
not recognized as a cholestatic compound
under CV; the ﬁnal SVMs correctly classi-
fied two of five animals in the test set,
despite the fact that these had been
treated with a lower dose (2.5 mg/kg) and
histopathology was only evident in animals
that received the high dose.
Because of the partial overlap of
compounds in the training and test set,
one would expect a smaller fraction of
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than with the more rigorous CV method.
This was indeed observed in most cases
(Tables 2 and 3) and emphasizes the extent
to which interpretation of results depends
on the details of the applied evaluation
method. Although in this case the number
of CV errors can provide information
about the generalization ability of a model,
the test performance should be regarded as
a measure for its consistency with respect
to a certain selection of compounds. For
our application we clearly wanted to opti-
mize the former; therefore, we used the
described CV scheme to select the best
SVMs. When we tentatively switched to a
more standard, leave-one-out procedure,
not a single CV error occurred. However,
the test accuracy was signiﬁcantly decreased,
indicating that a classiﬁer with less general-
ization ability had been generated by this
standard CV method.
The current model was based on
histopathologic and clinical chemistry data
and performs best on data comparable to
the training data. If there is no evidence
of toxicity (see deprenyl, lazabemide,
gentamicin), the gene expression profiles
are not wrongly assigned to a toxicity cate-
gory. Classification of lower but still
somewhat toxic doses was successful
with dichlorobenzene (1,500 mmol/kg),
amineptine (0.25 mmol/kg), aceta-
minophen (1,000 mg/kg), bromobenzene
(1 mmol/kg), Rx50 (1 mg/kg/day), Rx51
(0.13 mg/kg/day), and Rx60 (0.38 mg/
kg/day). Nevertheless, detection of toxic
substances applied at subtoxic doses can
be successful; examples include Rx10
(125 mg/kg/day) and some animals treated
with glibenclamide 2.5 mg/kg. However, it
is important to remember that the current
model was based on solid pathology and
therefore optimized for specificity. If bor-
derline or doses just below detectable
pathology were used to generate the model,
correct classification at subtoxic doses
could be expected in more cases. However,
an increase in sensitivity is expected to be
paid for by a reduced specificity (i.e.,
greater number of false positives).
If there were evidence for toxicity,
although with a lower histopathologic score
and less-pronounced clinical chemistry
changes, the model generally performed well,
as indicated by the relatively high test MCC
values. Examples for successful classiﬁcation
of earlier time points are Rx99 (24 hr) and
methylene dianiline (3 hr). However, very
early times can often affect a different set of
genes than those noted at later times (Heijne
et al. 2004; Ruepp et al. 2002).
Although the test set contained some of
the same compounds as the training set,
the experiments in the test set used lower
doses or samples collected at earlier time
points. Therefore, the high classification
accuracy observed with the test data indi-
cates good sensitivity of our models.
An interesting observation was that the
two experiments using chlorpromazine were
not equally well classiﬁed. Chlorpromazine
was expected to have a cholestatic effect at
the tested doses (Knodell 1975), but the
animals were classified predominantly as
nontoxic in the first experiment and as
cholestatic in the second experiment.
However, these differences in gene expres-
sion profiles are in agreement with differ-
ences in conventional end points, probably
because of biological and/or experimental
differences, as both experiments were per-
formed at different sites and with slightly
different sample processing protocols.
Summarizing, we demonstrated that
classification problems in toxicogenomics
can be effectively addressed by a supervised
learning approach. We applied SVMs on
microarray data from a set of model hepato-
toxicants. Combining SVM parameter opti-
mization with a compound-based external
CV scheme and (RFE), we were able to
obtain accurate classiﬁcation (i.e., high sen-
sitivity and specificity) of the compounds
included in the training set as well as for
previously unseen compounds. In addition,
RFE allowed us to select a relatively com-
pact subset of probe sets with potential use
as biomarkers. Thus, our results show that
toxicogenomics is a very powerful tool for
classification of compounds according to
their toxicity mechanism when a well-
designed database is combined with appro-
priate bioinformatics tools.
Despite these promising results, further
investigations must be performed to
increase the usefulness of transcript profil-
ing in toxicology. A larger database and
reﬁned analysis methods are anticipated to
further improve prediction accuracy.
We focused mainly on high doses that
led to clear toxicity as assessed by conven-
tional end points. However, it has been
reported that a compound affects different
genes and pathways depending on the
administered dose (Andrew et al. 2003).
Thus, a next step will be to include
expression proﬁles from lower doses in the
model-building process. Earlier time
points should also be considered. This will
allow us to assess whether gene expression
changes are already indicative of toxic lia-
bilities when standard parameters do not
yet detect toxicity. In addition, for classiﬁ-
cation purposes it is irrelevant whether the
gene expression changes considered
good discriminants for a toxic response
are causally linked to the toxicity.
Nevertheless, to gain further insight into a
specific MOT, it is valuable to interpret
results in a biological context, analyzing
the altered pathways and their relationship
to observed pathology or phenotype.
These investigations could help separate
transcriptional changes that are relevant
for the mode of toxicity from mere
bystander effects.
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